Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 93INDUSTRY 68NETWORK 8NIH 4OTHER_GOV 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3

Conditions

Cystadenocarcinoma, Serous 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Phantoms, Imaging 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Letrozole × 1 year × Clear all
NCT07391774 2026-06-05

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT00310180 2026-05-29

TAILORx

National Cancer Institute (NCI)

Phase 3 Active not recruiting
10,273 enrolled 14 charts
Breast

Breast Neoplasms

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡